https://www.selleckchem.com/pr....oducts/gilteritinib-
Buprenorphine medication assisted treatment (B-MAT) adherence for opioid use disorder (OUD) is suboptimal. reSET-O, an FDA-cleared prescription digital therapeutic, delivers neurobehavioral therapy (community-reinforcement approach+fluency training+contingency management) to B-MAT-treated OUD patients. This retrospective claims study (10/01/2018-10/31/2019) evaluated healthcare resource utilization up to 6months before/after reSET-O initiation. Repeated-measures negative binomial models compared incidences of encounters/pro
Like
Comment
Share
